2010Year1monthOn the 26th, Beike Biostem Cell Preparation Laboratory successfully passed the ISO9001 quality management system certification. On the previous January 23, the Jiangsu Provincial Stem Cell Bank under Beike Biotech passed the ISO9001 quality management system certification, and obtained the qualification certificate issued by my country Quality Certification Center 0px;border: 0px;font: inherit;vertical-align: baseline”> ISO9001 A comprehensive stem cell bank certified by the quality management system. Since then, Beike Biotech has obtained a series of certifications in the standardized preparation and research of adult stem cells, stem cell storage and technical support services, which further demonstrates Beike Biotech’s standardization in quality management and also marks that it has reached a new level in quality management.
As an attempt at a new model, Beike Biotechnology has jointly established Beike Stem Cell Industrialization R&D Base in Jiangsu Province with China Medical City, and established branches such as Jiangsu Beike Biotechnology Co., Ltd. and Jiangsu Provincial Stem Cell Bank. As the only stem cell bank in Jiangsu Province, the Jiangsu Provincial Stem Cell Bank is an important part of the Jiangsu Provincial Stem Cell and Biotherapy Public Technology Service Platform approved by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Stem Cell and Regenerative Medicine Engineering Center approved by the Jiangsu Provincial Development and Reform Commission, and the Jiangsu Provincial Stem Cell and Regenerative Medicine Base approved by the Jiangsu Provincial Department of Health.
Hu Xiang, chairman of Beike Biotechnology, said, “With the help of these public technical service platforms, we can integrate medical resources in Jiangsu Province, use the advantages of the platform, unify standards, improve management, and achieve the purpose of ensuring the safety of clinical application research. At present, this new model is developing well.”
from Beike BiologySince its establishment in 2005, in order to ensure the safety of clinical application research of stem cell technology, Beike Biotech has successively established a set of quality control systems and stem cell industrialization process management standards that are in line with the characteristics of stem cells and stem cell industrialization process management specifications with reference to the “Regulations on Human Organ Transplantation” issued by the Ministry of Health and other relevant laws and regulations, and actively referred to AABB/FACT related standards, continue to improve and improve the company’s existing quality control system, and innovatively carry out standardized management of the stem cell industry.
“National policies and regulations are constantly being improved. Beike Biotech has been following these policies and regulations, and constantly puts forward higher requirements for self-regulation and improvement. Innovating business models, strengthening channel construction, firming up the mainstream direction of regenerative medicine development, striving to achieve more breakthroughs in tissue replacement, repair and anti-aging, and promoting the development of stem cell industrialization and regenerative medicine in China.” Hu Xiang, chairman of Beike Biotech, is full of confidence in the future development of stem cell regenerative medicine.